Events Archives - Page 17 of 128

2 minute read

Arcellx Announces Continued Robust Long-Term Responses From Its CART-ddBCMA Phase 1 Expansion Trial In Patients With Relapsed Or Refractory Multiple Myeloma At ASH

December 8, 5:00 PM

-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months –-- The estimated median progression free

ACLX

1 minute read

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment In Ongoing Phase II Study Of BMF-219 In Adults With Type 2 Diabetes In Poster Presentation At WCIRDC

By Benzinga Newsdesk

December 8, 10:06 AM

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesAt Week 26, 22 weeks after the last dose of BMF-219, participants in the 100

BMEA

2 minute read

Eagle Pharmaceuticals To Present Abstract On Post-Hoc Analysis Of Amisulpride At The 77th PGA In New York City

By Benzinga Newsdesk

December 6, 5:29 PM

-- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration ("FDA") for rescue treatment of postoperative nausea and vomiting ("PONV") despite

EGRX

2 minute read

Validation Data On A Novel Prognostic Test Developed By GRAIL In Stage I Lung Cancer Presented At North America Conference On Lung Cancer

By Benzinga Newsdesk

December 6, 5:11 PM

Validation Results Using a Plasma-based Targeted Methylation Assay Demonstrate Potential to Identify High-Risk Patients who Might Benefit From Additional TreatmentGRAIL, LLC, a healthcare company whose mission is to

AZN

2 minute read

EXCLUSIVE: Fintech Experts Tackle Market Risks, Emerging Trends At Benzinga New York Event

By Tanzeel Akhtar

December 6, 1:01 PM

In a compelling panel discussion at Benzinga’s Fintech Deal Day event held in New York this November, industry experts gathered to delve into the complexities of managing market volatility and strategizing effect

VTI

3 minute read

BriaCell Highlights Outstanding Topline Survival And Clinical Benefit Data In Advanced Metastatic Breast Cancer At The 2023 SABCS

By Benzinga Newsdesk

December 6, 10:33 AM

Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*). 32 out of 42 patients treated

BCTX

1 minute read

Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research At The American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

December 6, 9:13 AM

A platform presentation will feature Dr. Enze Liu from the Indiana University School of Medicine sharing findings from a study on the use of optical genome mapping (OGM) to detect structural variants (SVs) in multiple

BNGO

1 minute read

Shattuck Labs To Host Investor Call And Webcast To Share Initial Clinical Trial Data From Phase 1A/B Dose-Expansion Cohorts In Frontline Higher-Risk Myelodysplastic Syndromes And TP53m Acute Myeloid Leukemia And Review Of Dose-Escalation Data From ASH

By Benzinga Newsdesk

December 5, 5:21 PM

Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with

STTK

1 minute read

Philip Morris International Inc. Presents At 2023 Morgan Stanley Global Consumer & Retail Conference; Sees FY23 Adjusted Diluted EPS $6.05-$6.08; Adjusted Diluted EPS, Excluding Currency $6.58-$6.61 Vs $6.11 Est.

By Benzinga Newsdesk

December 5, 11:04 AM

Full-Year 2023Forecast 2022 Reported Diluted EPS$4.95-$4.98 $

1 minute read

Alterity Therapeutics To Host Webcast To Discuss ATH434 Efficacy Data In Primates And Recent Clinical Progress

By Benzinga Newsdesk

December 4, 5:35 PM

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor

ATHE